Valeant Pharmaceuticals Intl (VRX) Given a $25.00 Price Target by Cantor Fitzgerald Analysts

Cantor Fitzgerald set a $25.00 price target on Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) in a report released on Monday, January 1st. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Other analysts also recently issued research reports about the stock. ValuEngine upgraded shares of Valeant Pharmaceuticals Intl from a hold rating to a buy rating in a report on Monday, October 2nd. TD Securities upgraded shares of Valeant Pharmaceuticals Intl from a hold rating to a buy rating and set a $20.00 price target for the company in a report on Friday, November 3rd. Vetr downgraded shares of Valeant Pharmaceuticals Intl from a strong-buy rating to a buy rating and set a $19.18 price target for the company. in a report on Monday, December 4th. TheStreet upgraded shares of Valeant Pharmaceuticals Intl from a d rating to a c- rating in a report on Tuesday, November 7th. Finally, HC Wainwright restated a hold rating and set a $17.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, October 4th. Six equities research analysts have rated the stock with a sell rating, ten have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $18.20.

Valeant Pharmaceuticals Intl (VRX) traded up $0.38 during mid-day trading on Monday, reaching $23.81. 11,701,107 shares of the company’s stock were exchanged, compared to its average volume of 15,499,089. The firm has a market cap of $8,320.00, a P/E ratio of 6.11, a price-to-earnings-growth ratio of 0.72 and a beta of -0.22. The company has a debt-to-equity ratio of 4.84, a quick ratio of 1.03 and a current ratio of 1.26. Valeant Pharmaceuticals Intl has a 12 month low of $8.31 and a 12 month high of $24.43.

In other Valeant Pharmaceuticals Intl news, Director John Paulson purchased 344,216 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was bought at an average price of $14.40 per share, with a total value of $4,956,710.40. Following the transaction, the director now directly owns 94,559 shares of the company’s stock, valued at approximately $1,361,649.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 5.87% of the company’s stock.

A number of hedge funds have recently modified their holdings of VRX. Marshall Wace North America L.P. purchased a new position in Valeant Pharmaceuticals Intl in the 2nd quarter valued at approximately $1,597,000. Airain ltd purchased a new stake in shares of Valeant Pharmaceuticals Intl during the 2nd quarter worth $667,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Valeant Pharmaceuticals Intl by 5.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 110,880 shares of the specialty pharmaceutical company’s stock worth $1,924,000 after purchasing an additional 6,054 shares during the last quarter. Private Advisor Group LLC lifted its position in shares of Valeant Pharmaceuticals Intl by 74.9% during the 2nd quarter. Private Advisor Group LLC now owns 25,633 shares of the specialty pharmaceutical company’s stock worth $428,000 after purchasing an additional 10,978 shares during the last quarter. Finally, Commonwealth Bank of Australia lifted its position in shares of Valeant Pharmaceuticals Intl by 0.7% during the 2nd quarter. Commonwealth Bank of Australia now owns 108,806 shares of the specialty pharmaceutical company’s stock worth $1,887,000 after purchasing an additional 800 shares during the last quarter. 49.45% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals Intl (VRX) Given a $25.00 Price Target by Cantor Fitzgerald Analysts” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/11/cantor-fitzgerald-analysts-give-valeant-pharmaceuticals-intl-vrx-a-25-00-price-target.html.

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply